Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effects of Vitamin D Supplementation on Depressive Symptoms in Type 2 Diabetes Mellitus Patients: Randomized Placebo-Controlled Double-Blind Clinical Trial Publisher Pubmed



Omidian M1 ; Mahmoudi M1 ; Abshirini M2 ; Eshraghian MR3 ; Javanbakht MH1 ; Zarei M1 ; Hasani H2 ; Djalali M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews Published:2019


Abstract

Aim: Diabetes increases the odds of depression and depression is often associated with poor glycemic control and complications of diabetes. Vitamin D is also believed to improve glycemic control and ameliorate depressive symptoms. Therefore, we examined effects of vitamin D monotherapy (without antidepressant drugs) on depressive symptoms in Type 2 diabetic patients with mild to moderate depressive symptoms. Methods: We conducted 12 weeks, placebo-controlled, double-blind, randomized trial on 68 subjects with T2DM and mild to moderate depressive symptoms. Subjects received 100 μg (4000 IU) vitamin D (n = 32) or placebo (n = 34) daily. Beck Depression Inventory-II (BDI–II–PERSIAN) was applied for assessment of the severity of depression. Depression scores and metabolic profiles were measured at the beginning and end of trail. Results: after 3 months of vitamin D supplementation, mean values of 25(OH) D increased from 15.5 ± 8.8 to 32.2 ± 8.9 ng/ml (p-value <0.001) in the vitamin D group. Moreover, BDI-II scores decreased from 15.2 ± 9.6 to 9.8 ± 7.2 (p-value <0.001) in the vitamin D group and 15.5 ± 11.2 to 13.7 ± 11.5 (p-value = 0.03) in placebo group. This decrease in BDI-II scores were significant (27.6% vs 10.8%) compared with placebo (p-value = 0.02). In term of metabolic profiles, mean change in level of Hemoglobin A1c (HbA1c), insulin and triglycerides (TG) were significantly higher in response to the treatment with vitamin D compared to placebo (p-value <0.02). Conclusions: In conclusion, supplementation of vitamin D in T2DM patients may protect these patients against the onset of major depressive disorder (MDD), with noticeable favorable effects on measures of metabolic profiles. Trial registration: NCT03008057 © 2019
Experts (# of related papers)
Other Related Docs
16. The Prevalence of Comorbid Depression in Patients With Diabetes: A Meta-Analysis of Observational Studies, Diabetes and Metabolic Syndrome: Clinical Research and Reviews (2019)